JP2022516389A5 - - Google Patents

Info

Publication number
JP2022516389A5
JP2022516389A5 JP2020566903A JP2020566903A JP2022516389A5 JP 2022516389 A5 JP2022516389 A5 JP 2022516389A5 JP 2020566903 A JP2020566903 A JP 2020566903A JP 2020566903 A JP2020566903 A JP 2020566903A JP 2022516389 A5 JP2022516389 A5 JP 2022516389A5
Authority
JP
Japan
Prior art keywords
inkt
chain variable
cells
car
scfv
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020566903A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022516389A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/035052 external-priority patent/WO2019232477A2/en
Publication of JP2022516389A publication Critical patent/JP2022516389A/ja
Publication of JP2022516389A5 publication Critical patent/JP2022516389A5/ja
Pending legal-status Critical Current

Links

JP2020566903A 2018-05-31 2019-05-31 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーＴ（ｉＮＫＴ）細胞 Pending JP2022516389A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862678883P 2018-05-31 2018-05-31
US62/678,883 2018-05-31
PCT/US2019/035052 WO2019232477A2 (en) 2018-05-31 2019-05-31 Genome-edited invariant natural killer t (inkt) cells for the treatment of hematologic malignancies

Publications (2)

Publication Number Publication Date
JP2022516389A JP2022516389A (ja) 2022-02-28
JP2022516389A5 true JP2022516389A5 (https=) 2022-06-07

Family

ID=68697140

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020566903A Pending JP2022516389A (ja) 2018-05-31 2019-05-31 血液悪性腫瘍を治療するためのゲノム編集インバリアントナチュラルキラーＴ（ｉＮＫＴ）細胞

Country Status (5)

Country Link
US (2) US20200040056A1 (https=)
EP (1) EP3801568A4 (https=)
JP (1) JP2022516389A (https=)
CN (1) CN112584844A (https=)
WO (1) WO2019232477A2 (https=)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102546839B1 (ko) 2016-08-03 2023-06-23 워싱턴 유니버시티 키메라 항원 수용체를 이용한 t 세포 악성종양의 치료를 위한 car-t 세포의 유전자 편집
AU2019372673A1 (en) 2018-11-01 2021-05-27 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for T cell engineering
CN109735558B (zh) * 2018-12-12 2022-04-15 中南大学 一种重组car19-il24基因、慢病毒载体、car19-il24-t细胞及应用
WO2020193628A1 (en) * 2019-03-25 2020-10-01 Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft Enhancement of cytolytic t-cell activity by inhibiting ebag9
WO2020232247A1 (en) 2019-05-14 2020-11-19 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
WO2021223359A1 (en) * 2020-05-06 2021-11-11 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
IL298999A (en) 2020-06-11 2023-02-01 Provention Bio Inc Methods and compositions for the prevention of type 1 diabetes
CN116600818A (zh) * 2020-10-28 2023-08-15 贝勒医学院 靶向免疫细胞中的src-3作为治疗癌症的免疫调节治疗剂
CN112225822B (zh) * 2020-12-14 2021-03-23 北京基因启明生物科技有限公司 高扩增、存续能力和杀瘤作用的CAR-iNKT及应用
EP4039808A1 (en) * 2021-02-08 2022-08-10 Ospedale San Raffaele S.r.l. Guide rnas and uses thereof
CN112961854B (zh) * 2021-02-20 2022-03-29 中国人民解放军总医院第五医学中心 一种靶向IL-16基因的sgRNA、质粒组及基因敲除方法和应用
CN112980800A (zh) * 2021-03-08 2021-06-18 河北森朗生物科技有限公司 Car-t细胞、其构建方法及其应用
CN113061624B (zh) * 2021-03-09 2023-08-18 矫士平 一种敲除Tim-3基因以延长T细胞体内生存的方法
JP2024520444A (ja) 2021-05-24 2024-05-24 プロヴェンション・バイオ・インコーポレイテッド １型糖尿病を治療するための方法
CN115989244A (zh) * 2021-08-06 2023-04-18 上海驯鹿生物技术有限公司 Cd5和cd7双靶点的全人源嵌合抗原受体(car)及其应用
JP2025508834A (ja) * 2022-02-23 2025-04-10 ティンケソ セラピューティクス，インコーポレーテッド キメラ抗原受容体を発現する改変インバリアントナチュラルキラーｔ細胞及びその使用
CN114644716A (zh) * 2022-04-07 2022-06-21 苏州大学 一种抗bxmas1嵌合抗原受体及其修饰的免疫细胞及应用
CN119997968A (zh) * 2022-08-23 2025-05-13 帝国理工学院创新有限公司 TCR β链可变区的嵌合抗原受体（CAR）
CN119529098B (zh) * 2025-01-22 2025-05-30 北京可瑞生物科技有限公司 对mage-a1具有特异性的结合分子和抗cd3的融合蛋白

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011149881A2 (en) * 2010-05-24 2011-12-01 Children's Medical Center Corporation Methods for the treatment and prevention of inflammatory diseases
WO2015112793A2 (en) * 2014-01-27 2015-07-30 St. Jude Children's Research Hospital, Inc. Methods of expanding ex vivo natural killer t (nkt) cells and therapeutic uses thereof
CA3280968A1 (en) * 2015-04-23 2025-10-30 Baylor College Of Medicine Nkt-cell subset for in vivo persistence and therapeutic activity and propagation of same
AU2016361451B2 (en) * 2015-11-27 2024-01-25 Cartherics Pty. Ltd. Genetically modified cells and uses thereof
SG11201805186VA (en) * 2016-01-20 2018-07-30 Fate Therapeutics Inc Compositions and methods for immune cell modulation in adoptive immunotherapies
EP3548049A4 (en) * 2016-12-05 2020-07-22 Fate Therapeutics, Inc. COMPOSITIONS AND METHODS FOR MODULATION OF IMMUNE CELLS IN ADOPTIVE IMMUNOTHERAPIES
EP3612210A4 (en) * 2017-04-19 2021-01-27 Board Of Regents, The University Of Texas System MANIPULATED ANTIGEN RECEPTORS EXPRESSING IMMUNE CELLS
CN107384949B (zh) * 2017-06-27 2019-01-15 闾民 表达GPC3嵌合抗原受体的iNKT细胞及制备、应用
EP3802578A4 (en) * 2018-06-01 2022-03-23 Washington University SUPPRESSION OF CYTOKINE RELEASE SYNDROME IN CHIMERIC ANTIGEN RECEPTOR CELL THERAPY
WO2020232427A2 (en) * 2019-05-16 2020-11-19 Arch Oncology, Inc. Therapeutic compositions and methods for treating cancer in combination with analogs of interleukin proteins

Similar Documents

Publication Publication Date Title
JP2022516389A5 (https=)
JP2021525524A5 (https=)
JP7514746B2 (ja) 細胞
EP3586852B1 (en) Modified cell expansion and uses thereof
Zhang et al. Engineering car-t cells
Cartellieri et al. Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts
JP7179030B2 (ja) Ｒｏｒ１ ｃａｒ ｔ細胞
Chmielewski et al. T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity
JP2024174023A (ja) キメラ抗原受容体
KR20200015713A (ko) 항-trbc1 항원 결합 도메인
JP2015527070A5 (https=)
CN112638947A (zh) 用于治疗实体瘤的嵌合抗原受体细胞
CN107406517A (zh) 包含cd19结合域的嵌合抗原受体(car)
KR102316091B1 (ko) Bcma를 표적으로 하는 키메라 항원 수용체 및 이의 용도
Qian et al. The novel anti-CD19 chimeric antigen receptors with humanized scFv (single-chain variable fragment) trigger leukemia cell killing
Maruta et al. Direct comparison of target-reactivity and cross-reactivity induced by CAR-and BiTE-redirected T cells for the development of antibody-based T-cell therapy
JP2024546999A5 (https=)
Hombach et al. T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30+ cutaneous lymphoma cells
Märkl et al. Mutation-specific CAR T cells as precision therapy for IGLV3-21R110 expressing high-risk chronic lymphocytic leukemia
JP2025534161A (ja) 線維芽細胞活性化タンパク質（ｆａｐ）ｃａｒインバリアントナチュラルキラーｔ細胞及びその使用
EP3912992A1 (en) Car library and production method for scfv
Shirasu et al. Molecular Characterization of a Fully Human Chimeric T‐Cell Antigen Receptor for Tumor‐Associated Antigen EpCAM
Blanco et al. Autocrine costimulation: Tumor-specific CD28-mediated costimulation of T cells by in situ production of a bifunctional B7–anti-CEA diabody fusion protein
EP4606823A1 (en) Synthetic t cell receptor antigen receptor specifically binding to lilrb4 and use thereof
WO2026019829A1 (en) Compositions and methods for stimulating t cells used in cell therapy with a bispecific bridging molecule